(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 29 September 2016 - Actelion Ltd (SIX: ATLN) announced today that it will investigate the use of combination therapy with ponesimod and dimethyl fumarate (Tecfidera) for patients with relapsing multiple sclerosis (RMS). The POINT study - which will be conducted under a Special Protocol Assessment (SPA) agreement with the FDA - is the first to assess an all-oral treatment paradigm with the objective to better control this progressive, debilitating neurological disorder. Despite recent advances in the treatment of RMS, there remains a considerable medical need for improved long-term disease control without compromising patient safety. While...
↧